News

January 31, 2008 1:36 PM

CLARITIN® Signs First-Time Sponsorship Agreement with Allergy Sufferer and NASCAR Sprint Cup Driver Carl Edwards

- Partnership Drives Home Importance of Being Alert and Focused on and off the Racetrack -

KENILWORTH, NJ, Jan. 31, 2008 – Schering-Plough (NYSE:SGP), makers of the non-drowsy allergy medication, CLARITIN®, today announced a first-time sponsorship deal with NASCAR star and allergy sufferer Carl Edwards for the 2008 Sprint Cup racing season. Edwards, a member of the Roush Fenway Racing team and 2007 Busch Series champion, will drive the No. 99 CLARITIN Ford Fusion during selected spring races, and CLARITIN branding will appear on his No. 99 Office Depot Ford Fusion and firesuit throughout the season.

Edwards, who takes CLARITIN to treat his severe allergy symptoms, will serve as spokesperson for CLARITIN’s “Clear to Drive” campaign. He will also be featured in the CLARITIN brand’s new advertising campaign, debuting during Sunday’s telecast of the Super Bowl. Additionally, a sweepstakes launching later this year will give five lucky NASCAR fans the opportunity to win a trip around the track with Edwards, and one will win a Ford Mustang.

“When I’m driving at 180 miles per hour, I can’t risk taking a medicine that makes me drowsy. That’s why I only use non-drowsy CLARITIN to treat my worst allergy symptoms,” said Edwards.

“CLARITIN is proud to sponsor Carl Edwards as he pursues the 2008 NASCAR Sprint Cup Series championship,” said TJ Higgins, Group Vice President, Marketing, Schering-Plough Consumer Healthcare. “Nobody knows better than Carl how important it is to be alert and focused while driving. Like Carl, millions of allergy sufferers nationwide choose CLARITIN for effective relief from indoor and outdoor allergies without drowsiness.”

Edwards will also record a radio announcement to educate consumers about the dangers of drowsy driving, which is a growing safety problem in the U.S. and can potentially result from taking medicines that can cause drowsiness. “Drowsy driving is incredibly dangerous, and I’m pleased to be working with CLARITIN to launch the ‘Clear to Drive’ campaign. I want to make sure people know how important it is to read the labels of products and understand the potential side effects before they get behind the wheel.”

About Roush Fenway Racing

Roush Fenway Racing is NASCAR’s largest team operating 13 motorsports teams. Five in the NASCAR Sprint Cup Series with drivers Matt Kenseth, Jamie McMurray, Greg Biffle, Carl Edwards and David Ragan; four in the Nationwide Series with Kenseth, Biffle, Edwards, McMurray, Ragan, Erik Darnell and Colin Braun; and three in the Craftsman Truck Series with Darnell, Braun and Joey Clanton; and one in the ARCA RE/MAX Series with Ricky Stenhouse Jr.

About CLARITIN®

All CLARITIN® brand products are available without a prescription, including: CLARITIN® Tablets, a once-daily full prescription strength, non-drowsy formulation; CLARITIN® RediTabs® Tablets, a novel once-daily formulation in a quickly dissolving tablet for ages 6 and older; CLARITIN-D® 24-hour and 12-hour Extended Release Tablets, with the decongestant pseudoephedrine now located behind the counter; CHILDREN’S CLARITIN® Syrup, a liquid formulation for children ages 2 and older in grape and fruit flavors; CHILDREN’S CLARITIN® Grape Chewables, a chewable tablet for children ages 2 and older; and CLARITIN Hives Relief™ tablets.

CLARITIN® is the No. 1 physician-recommended and pediatrician-recommended over-the-counter antihistamine brand for allergic rhinitis. The CLARITIN® Rx-to-OTC switch in 2002 was the largest switch ever—and the first and only for a non-sedating antihistamine. For more information on allergies and treatment, visit www.CLARITIN.com.

About Schering-Plough

Schering-Plough Consumer Health Care is the U.S. over-the-counter (OTC) and consumer products business unit of Schering-Plough an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

Follow Roush on

Copyright 2014 Roush Fenway Racing. All Rights Reserved